M. Fina

发表

Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma

S. Pileri, M. Baccarani, P. Zinzani, 2005, Leukemia & lymphoma.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

S. Pileri, M. Baccarani, S. Fanti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

S. Pileri, M. Baccarani, V. Ambrosini, 2009 .

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0–1) diffuse large B-cell lymphoma

S. Pileri, M. Baccarani, P. Zinzani, 2009, Leukemia & lymphoma.

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, S. Fanti, 2010, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas

S. Pileri, M. Baccarani, P. Zinzani, 2005, Leukemia & lymphoma.

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.

S. Pileri, M. Baccarani, S. Fanti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

S. Pileri, M. Baccarani, S. Fanti, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, P. Zinzani, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

S. Pileri, M. Baccarani, E. Sabattini, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

S. Pileri, M. Baccarani, P. Zinzani, 2005, Haematologica.

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

S. Pileri, M. Gobbi, M. Baccarani, 2008, The Lancet. Oncology.

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2008, Cancer.

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

S. Pileri, M. Baccarani, P. Zinzani, 2007, Leukemia & lymphoma.

Phase II Trial of Short-Course R-Chop Followed by 90 Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

S. Pileri, M. Baccarani, S. Fanti, 2010 .

Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.

M. Baccarani, P. Zinzani, L. Alinari, 2005, Haematologica.

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

S. Pileri, M. Baccarani, S. Fanti, 2010, Clinical Cancer Research.

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.

M. Baccarani, S. Fanti, P. Zinzani, 2007, Clinical lymphoma & myeloma.

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

S. Pileri, M. Baccarani, S. Fanti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network

P. Mazza, A. Guarini, G. Tarantini, 2022, Cancers.

Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy

M. Baccarani, P. Zinzani, L. Alinari, 2005, Leukemia & lymphoma.

CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission

P. Zinzani, E. Derenzini, A. Broccoli, 2009, Journal of Neuro-Oncology.

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

S. Pileri, M. Baccarani, R. Trisolini, 2007, Haematologica.

Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

M. Baccarani, P. Zinzani, E. Marchi, 2006 .

Role of Anemia in Survival of Elderly Aggressive Non-Hodgkin’s Lymphoma Patients Following Chemotherapy.

M. Baccarani, P. Zinzani, L. Alinari, 2004 .

A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma.

F. Angrilli, V. Pavone, P. Zinzani, 2014 .

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, S. Fanti, 2010, Clinical lymphoma, myeloma & leukemia.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

S. Pileri, M. Baccarani, S. Fanti, 2012, Annals of Oncology.

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2008, Cancer.

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, P. Zinzani, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

S. Pileri, M. Baccarani, P. Zinzani, 2005, Haematologica.

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.

V. Ambrosini, S. Fanti, P. Zinzani, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan ( 90 Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

M. Baccarani, S. Fanti, P. Zinzani, 2009 .

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

S. Pileri, M. Baccarani, S. Fanti, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.